The PIP breast implants — 300,000 Women Filled With Secret Industrial Silicone

When France’s medical-safety agency AFSSAPS suspended Poly Implant Prothèse’s silicone breast implants and forced the company into liquidation in March 2010, the gap between what founder Jean-Claude Mas had sold and what he had actually manufactured had been hidden for nearly a decade: since roughly 2001, PIP had quietly filled most of its implants with an in-house industrial-grade silicone — a gel built from chemicals such as Baysilone, Silopren, and Rhodorsil intended for fuel additives and rubber, not the medical-grade material on its certificates. The substitution cut the gel cost by close to 90 percent, from on the order of €35 per litre to roughly €5. The legend PIP traded on — a cut-price, CE-marked, third-largest implant maker in the world — was, for most of the prostheses it shipped, a fraud the company kept two sets of records to conceal.

The harm was mechanical and then systemic. The unapproved gel sat in shells that ruptured and leaked at rates independent reviews placed between 5 and 11 percent, against under 1 percent for approved implants — an elevation on the order of fivefold. When the shells failed, the industrial filler bled into surrounding tissue, provoking inflammation, lymph-node reactions, and repeat surgery. By the end of 2011, regulators were tracking roughly twenty cancer cases among PIP recipients and one death attributed to anaplastic large-cell lymphoma, though no causal link to the silicone was ever established. An estimated 300,000 women in some 65 countries carried the devices, many fitted for breast reconstruction after cancer.

Recall did not mean retrieval. Pulling the product and liquidating the maker left hundreds of thousands of devices inside bodies; on 23 December 2011 the French government went further than most and recommended that about 30,000 French women have the implants removed as a precaution. Criminal justice followed the bankruptcy: a Marseille court convicted Mas of aggravated fraud on 10 December 2013, sentencing him to four years in prison and a €75,000 fine and barring him from medicine and company management — upheld on appeal at Aix-en-Provence in May 2016. The deeper failure was the certification chain: notified body TÜV Rheinland had inspected PIP repeatedly between the late 1990s and 2010 without catching the swap, and in May 2021 the Paris Court of Appeal found it negligent and liable to victims. The scandal became the proximate fuel for the European Union’s 2017 Medical Device Regulation, the law written to close the door PIP had walked through.